In vitro sensitivity to methyl-prednisolone is associated with clinical response in pediatric idiopathic nephrotic syndrome

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 3, 2016, Pages 268-274

  Cuzzoni, E ^a   De Iudicibus, S ^b   Stocco, G ^a   Favretto, D ^b   Pelin, M ^a   Messina, G ^c   Ghio, L ^d   Monti, E ^e   Pasini, A ^e   Montini, G ^d   Decorti, G ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c POLICLINICO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Nephrology and Dialysis Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CELL PROLIFERATION; CHILD; DRUG SENSITIVITY; FEMALE; HUMAN; IC50; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THYMIDINE INCORPORATION ASSAY; TREATMENT RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MONONUCLEAR CELL; PROSPECTIVE STUDY; RECURRENT DISEASE; TIME FACTOR;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; METHYLPREDNISOLONE; NEPHROTIC SYNDROME; PROSPECTIVE STUDIES; RECURRENCE; TIME FACTORS;

EID: 84988981860     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.372     Document Type: Article

References (34)

1. Pasini, A. et al. Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr. Nephrol. 30, 91–101 (2015).
2. Lombel, R.M., Gipson, D.S. & Hodson, E.M. Kidney Disease: Improving Global O: treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr. Nephrol. 28, 415–426 (2013).
3. Lombel, R.M., Hodson, E.M. & Gipson, D.S. Kidney Disease: Improving Global O: treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr. Nephrol. 28, 409–414 (2013).
4. Lane, J.C. & Kaskel, F.J. Pediatric nephrotic syndrome: from the simple to the complex. Semin. Nephrol. 29, 389–398 (2009).
5. Teeninga, N. et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int. 85, 1444–1453 (2014).
6. Eddy, A.A. & Symons, J.M. Nephrotic syndrome in childhood. Lancet 362, 629–639 (2003).
7. Hodson, E.M., Willis, N.S. & Craig, J.C. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. 17, CD001533 (2007).
8. Andersen, R.F., Thrane, N., Noergaard, K., Rytter, L., Jespersen, B. & Rittig, S. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr. Nephrol. 25, 1299–1304 (2010).
9. Kabuki, N., Okugawa, T., Hayakawa, H., Tomizawa, S., Kasahara, T. & Uchiyama, M. Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 12, 467–470 (1998).
10. Schachter, A.D. The pediatric nephrotic syndrome spectrum: clinical homogeneity and molecular heterogeneity. Pediatr. Transplant. 8, 344–348 (2004).
11. Vivarelli, M., Moscaritolo, E., Tsalkidis, A., Massella, L. & Emma, F. Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. J. Pediatr. 156, 965–971 (2010).
12. Yap, H.K., Han, E.J., Heng, C.K. & Gong, W.K. Risk factors for steroid dependency in children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 16, 1049–1052 (2001).
13. Kirkham, B.W., Corkill, M.M., Davison, S.C. & Panayi, G.S. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J. Rheumatol. 18, 821–825 (1991).
14. Seki, M. et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum. 41, 823–830 (1998).
15. Hirano, T., Homma, M., Oka, K., Tsushima, H., Niitsuma, T. & Hayashi, T. Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids. Immunopharmacology 40, 57–66 (1998).
16. Langhoff, E. et al. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1, 1296–1297 (1986).
17. Hirano, T., Akashi, T., Kido, T., Oka, K., Shiratori, T. & Miyaoka, M. Immunosuppressant pharmacodynamics on peripheral-blood mononuclear cells from patients with ulcerative colitis. Int. Immunopharmacol. 2, 1055–1063 (2002).
18. Hearing, S.D., Norman, M., Smyth, C., Foy, C. & Dayan, C.M. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J. Clin. Endocrinol. Metab. 84, 4149–4154 (1999).
19. Lowy, M.T., Reder, A.T., Gormley, G.J. & Meltzer, H.Y. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the dexamethasone suppression test. Biol. Psychiatry 24, 619–630 (1988).
20. Carlotti, A.P. et al. Glucocorticoid receptors, in vitro steroid sensitivity, and cytokine secretion in idiopathic nephrotic syndrome. Kidney Int. 65, 403–408 (2004).
21. Cuzzoni, E., De Iudicibus, S., Bartoli, F., Ventura, A. & Decorti, G. Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br. J. Clin. Pharmacol. 73, 651–655 (2012).
22. Chriguer, R.S., Elias, L.L., da Silva, I.M. Jr., Vieira, J.G., Moreira, A.C. & de Castro, M. Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies. J. Clin. Endocrinol. Metab. 90, 5978–5984 (2005).
23. Abeyagunawardena, A.S. & Trompeter, R.S. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch. Dis. Child. 93, 226–228 (2008).
24. Leisti, S., Vilska, J. & Hallman, N. Adrenocortical insufficiency and relapsing in the idiopathic nephrotic syndrome of childhood. Pediatrics 60, 334–342 (1977).
25. MacDonald, N.E., Wolfish, N., McLaine, P., Phipps, P. & Rossier, E. Role of respiratory viruses in exacerbations of primary nephrotic syndrome. J. Pediatr. 108, 378–382 (1986).
26. Yap, H.K., Cheung, W., Murugasu, B., Sim, S.K., Seah, C.C. & Jordan, S.C. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J. Am. Soc. Nephrol. 10, 529–537 (1999).
27. Arbeitsgemeinschaft fur padiatrische nephrologie. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Lancet 1(8582), 380–383 (1988).
28. Indian Pediatric Nephrology Group IaOP, Bagga, A. et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 45(3), 203–214 (2008).
29. Chang, J.W., Tsai, H.L., Wang, H.H. & Yang, L.Y. Clinicopathological features and prognosis of Chinese children with idiopathic nephrotic syndrome between different age groups. Eur. J. Clin. Pediatr. 168, 1189–1194 (2009).
30. Gulati, S., Kher, V., Sharma, R.K. & Gupta, A. Steroid response pattern in Indian children with nephrotic syndrome. Acta Paediatr. 83, 530–533 (1994).
31. Gulati, S., Sural, S., Sharma, R.K., Gupta, A. & Gupta, R.K. Spectrum of adolescent-onset nephrotic syndrome in Indian children. Pediatr. Nephrol. 16, 1045–1048 (2001).
32. Kim, J.S., Bellew, C.A., Silverstein, D.M., Aviles, D.H., Boineau, F.G. & Vehaskari, V.M. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int. 68, 1275–1281 (2005).
33. Takeda, A., Takimoto, H., Mizusawa, Y. & Simoda, M. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 16, 888–893 (2001).
34. Kurata, Y. et al. Pretransplant pharmacodynamic analysis of immunosuppressive agents using CFSE-based T-cell proliferation assay. Clin. Pharmacol. Ther. 86, 285–289 (2009).